Table 1 General demographics and baseline measures for the OEA and placebo groups.

From: Oleoylethanolamide supplementation improves mood and reduces fatigue in veterans with GWI in a 15-week randomized, double-blind, placebo-controlled exploratory clinical trial

General demographics

Placebo

OEA

p-value

(n = 26)

(n = 26)

Age (years)

mean ± SD

59 ± 5

58 ± 5

0.46

Sex, n (%)

Male

23 (89)

26 (100)

0.23

Female

3 (11)

0 (0)

Race, n (%)

White/Caucasian

22 (85)

19 (73)

0.50

Black/African American

04 (15)

06 (23)

Other/Multiracial

00 (00)

01 (04)

Ethnicity, n (%)

Non-Hispanic/Latino

22 (85)

22 (85)

1.00

Hispanic/Latino

04 (15)

04 (15)

Education, n (%)

12 years (High School Diploma/GED)

03 (12)

03 (12)

0.40

13–15 years

(Associate degree/

2-year college/Other)

13 (50)

16 (62)

16-years

(Bachelor’s degree)

06 (23)

03 (12)

17 + years (Advanced or professional degree)

04 (15)

04 (15)

Weight (kg)

mean ± SD

100 ± 21.4

98 ± 18.3

0.82

BMI ± SD

32.5 ± 5.1

30.2 ± 5.7

0.14

Cannabis use, n (%)

3 (12)

3 (12)

1.00

CNS vital sign test

NCI ± SD

213 ± 30

211 ± 20

0.76

RBANS (sum of index) mean ± SD

439 ± 59.4

430 ± 47.2

0.56

MFI-20, mean ± SD

76 ± 17.3

70 ± 16.6

0.22

POMS, mean ± SD

27 ± 32.3

21 ± 32.6

0.52

*SF-McGill pain questionnaire,

mean ± SD

14.4 ± 12.1

14.5 ± 11.6

0.98

  1. *Data unavailable for 8 participants for whom the full version of this test was used. Note: No statistically significant differences were observed at baseline between the placebo and control groups (p > 0.05). Multifunctional Fatigue Inventory 20 (MFI20), abbreviated Profiles of Mood States (POMS) and Repeatable Battery for the Assessment of Neuropsychological Status RBANS), Neurocognitive index (NCI) and Short-form McGill Pain Questionnaire.
Back to article page